Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert Lakomy is active.

Publication


Featured researches published by Robert Lakomy.


Journal of Immunology | 2004

Antisense Oligonucleotides Down-Regulating Costimulation Confer Diabetes-Preventive Properties to Nonobese Diabetic Mouse Dendritic Cells

Jennifer Machen; Jo Harnaha; Robert Lakomy; Alexis Styche; Massimo Trucco; Nick Giannoukakis

Phenotypically “immature” dendritic cells (DCs), defined by low cell surface CD40, CD80, and CD86 can elicit host immune suppression in allotransplantation and autoimmunity. Herein, we report the most direct means of achieving phenotypic immaturity in NOD bone marrow-derived DCs aiming at preventing diabetes in syngeneic recipients. CD40, CD80, and CD86 cell surface molecules were specifically down-regulated by treating NOD DCs ex vivo with a mixture of antisense oligonucleotides targeting the CD40, CD80, and CD86 primary transcripts. The incidence of diabetes was significantly delayed by a single injection of the engineered NOD DCs into syngeneic recipients. Insulitis was absent in diabetes-free recipients and their splenic T cells proliferated in response to alloantigen. Engineered DC promoted an increased prevalence of CD4+CD25+ T cells in NOD recipients at all ages examined and diabetes-free recipients exhibited significantly greater numbers of CD4+CD25+ T cells compared with untreated NOD mice. In NOD-scid recipients, antisense-treated NOD DC promoted an increased prevalence of these putative regulatory T cells. Collectively, these data demonstrate that direct interference of cell surface expression of the major costimulatory molecules at the transcriptional level confers diabetes protection by promoting, in part, the proliferation and/or survival of regulatory T cells. This approach is a useful tool by which DC-mediated activation of regulatory T cells can be studied as well as a potential therapeutic option for type 1 diabetes.


Journal of Biological Chemistry | 2002

Immunosuppressive effects of glucosamine.

Linlin Ma; William A. Rudert; Jo Harnaha; Marietta Wright; Jennifer Machen; Robert Lakomy; Shiguang Qian; Lina Lu; Paul D. Robbins; Massimo Trucco; Nick Giannoukakis

Glucosamine is a naturally occurring derivative of glucose and is an essential component of glycoproteins and proteoglycans, important constituents of many eukaryotic proteins. In cells, glucosamine is produced enzymatically by the amidation of glucose 6-phosphate and can then be further modified by acetylation to result in N-acetylglucosamine. Commercially, glucosamine is sold over-the-counter to relieve arthritis. Although there is evidence in favor of the beneficial effects of glucosamine, the mechanism is unknown. Our data demonstrate that glucosamine suppresses the activation of T-lymphoblasts and dendritic cells in vitroas well as allogeneic mixed leukocyte reactivity in a dose-dependent manner. There was no inherent cellular toxicity involved in the inhibition, and the activity was not reproducible with other amine sugars. More importantly, glucosamine administration prolonged allogeneic cardiac allograft survival in vivo. We conclude that, despite its documented effects on insulin sensitivity, glucosamine possesses immunosuppressive activity and could be beneficial as an immunosuppressive agent.


Diabetes | 2008

A Microsphere-Based Vaccine Prevents and Reverses New-Onset Autoimmune Diabetes

Brett E. Phillips; Karen Nylander; Jo Harnaha; Jennifer Machen; Robert Lakomy; Alexis Styche; Kimberly A. Gillis; Larry Brown; Debra Lafreniere; Michael Gallo; Janet Knox; Kenneth Hogeland; Massimo Trucco; Nick Giannoukakis

OBJECTIVE—This study was aimed at ascertaining the efficacy of antisense oligonucleotide-formulated microspheres to prevent type 1 diabetes and to reverse new-onset disease. RESEARCH DESIGN AND METHODS—Microspheres carrying antisense oligonucleotides to CD40, CD80, and CD86 were delivered into NOD mice. Glycemia was monitored to determine disease prevention and reversal. In recipients that remained and/or became diabetes free, spleen and lymph node T-cells were enriched to determine the prevalence of Foxp3+ putative regulatory T-cells (Treg cells). Splenocytes from diabetes-free microsphere-treated recipients were adoptively cotransferred with splenocytes from diabetic NOD mice into NOD-scid recipients. Live-animal in vivo imaging measured the microsphere accumulation pattern. To rule out nonspecific systemic immunosuppression, splenocytes from successfully treated recipients were pulsed with β-cell antigen or ovalbumin or cocultured with allogeneic splenocytes. RESULTS—The microspheres prevented type 1 diabetes and, most importantly, exhibited a capacity to reverse clinical hyperglycemia, suggesting reversal of new-onset disease. The microspheres augmented Foxp3+ Treg cells and induced hyporesponsiveness to NOD-derived pancreatic β-cell antigen, without compromising global immune responses to alloantigens and nominal antigens. T-cells from successfully treated mice suppressed adoptive transfer of disease by diabetogenic splenocytes into secondary immunodeficient recipients. Finally, microspheres accumulated within the pancreas and the spleen after either intraperitoneal or subcutaneous injection. Dendritic cells from spleen of the microsphere-treated mice exhibit decreased cell surface CD40, CD80, and CD86. CONCLUSIONS—This novel microsphere formulation represents the first diabetes-suppressive and reversing nucleic acid vaccine that confers an immunoregulatory phenotype to endogenous dendritic cells.


Cellular & Molecular Immunology | 2012

Treg cells in pancreatic lymph nodes: the possible role in diabetogenesis and β cell regeneration in a T1D model

Benjamin K Nti; Janet L Markman; Suzanne Bertera; Alexis Styche; Robert Lakomy; Vladimir Subbotin; Massimo Trucco; Tatiana D. Zorina

Previously, we established a model in which physiologically adequate function of the autologous β cells was recovered in non-obese diabetic (NOD) mice after the onset of hyperglycemia by rendering them hemopoietic chimera. These mice were termed antea-diabetic. In the current study, we addressed the role of T regulatory (Treg) cells in the mechanisms mediating the restoration of euglycemia in the antea-diabetic NOD model. The data generated in this study demonstrated that the numbers of Treg cells were decreased in unmanipulated NOD mice, with the most profound deficiency detected in the pancreatic lymph nodes (PLNs). The impaired retention of the Treg cells in the PLNs correlated with the locally compromised profile of the chemokines involved in their trafficking, with the most prominent decrease observed in SDF-1. The amelioration of autoimmunity and restoration of euglycemia observed in the antea-diabetic mice was associated with restoration of the Treg cell population in the PLNs. These data indicate that the function of the SDF-1/CXCR4 axis and the retention of Treg cells in the PLNs have a potential role in diabetogenesis and in the amelioration of autoimmunity and β cell regeneration in the antea-diabetic model. We have demonstrated in the antea-diabetic mouse model that lifelong recovery of the β cells has a strong correlation with normalization of the Treg cell population in the PLNs. This finding offers new opportunities for testing the immunomodulatory regimens that promote accumulation of Treg cells in the PLNs as a therapeutic approach for type 1 diabetes (T1D).


BioTechniques | 2011

An improved intracellular staining protocol for efficient detection of nuclear proteins in YFP-expressing cells.

Maria Grupillo; Robert Lakomy; Xuehui Geng; Alexis Styche; William A. Rudert; Massimo Trucco; Yong Fan

Intracellular staining is a widely used flow cytometry (FCM)-based technique to detect the expression of cytoslio nucleic antigens. However, intracellular staining of cells expressing cytosolic fluorescent protein (FP) markers was proven to be problematic as significant loss of the FP-signal was routinely observed. Using splenocytes harvested from mice constitutively expressing the enhanced yellow fluorescent proteins (YFP) as a model, we modified the widely used intracellular staining protocol and successfully achieved simultaneous detection of both the nuclear proteins and YFP in T-regulatory cells. The improved protocol can be used to perform antibody-based intracellular characterization of FP-labeled target cells, while maintaining their fluorescent reporter signals for easy tracing and identification.


Lung Cancer | 1988

Chapter 9 Monoclonal antibodies directed against small cell carcinomas define by flow cytometry phenotypic differences among small cell and non-small cell carcinomas, neuroblastomas, and lymphoblastoid cell line

Aurelia M. C. Koros; Robert Lakomy; Marc Wagner; John H. Lange; John C. Hiserodt; Edwin Klein

Abstract Indirect immunofluorescence and flow cytometry were used to determine reactivity of workshop antibodies with a large panel of human cultured cell lines which included small cell lung carcinoma (SCLC) “classic”, and “variant”; and non-small cell lung carcinomas (NSCLC). Other cell lines were SHP-77 1 (an unusual “oat cell” large cell variant which has the morphology of a “variant”, but biochemical properties of a “classic” SCLC). Also studied were 2 neuroblastoma lines, 2 colon carcinoma and 5 lymphoblastoid lines. Three morphologically similar “classic” SCLC were phenotypically different in reactivity with workshop antibodies, suggesting that testing with such a panel is a new means to classify SCLC. The “classic” lines also differed in intensity of labelling with some of the reactive monoclonals, indicating differences in density of surface markers. Xenografts of human tumour lines grown in nude mice reacted very strongly with (FAB 1 ) 2 anti-mouse fragments, suggesting that such xenografts have nude mouse immunoglobulins on their surface. Evidence is presented that some monoclonals may react with tumour cells via Fc receptors NCSCLC, colon carcinoma, and lymphoblastoid lines also react with some workshop antibodies.


Diabetes | 2006

Interleukin-7 Is a Survival Factor for CD4 CD25 T-Cells and Is Expressed by Diabetes-Suppressive Dendritic Cells

Jo Harnaha; Jennifer Machen; Marietta Wright; Robert Lakomy; Alexis Styche; Massimo Trucco; Sami Makaroun; Nick Giannoukakis


Immunologic Research | 2011

A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice

Ming S. Lin; Hubert M. Tse; Meghan M. Delmastro; Suzanne Bertera; Caterina T. Wong; Robert Lakomy; Jing He; Martha M. Sklavos; Gina M. Coudriet; Massimo Pietropaolo; Massimo Trucco; Jon D. Piganelli


Cancer Research | 1985

Stability and utility of the unique human small cell carcinoma line SHP-77.

Aurelia M. C. Koros; Edwin Klein; Sylvia Pan; R. Wayne Atchison; Robert Lakomy; Alfred B. Bahnson; Carol Sherer


Diabetes | 2018

Prolongation of Allograft Survival by Intrathymic Introduction of Allogeneic Thymic Epithelial Cells

Isha Pradhan; Stephanie Wong-Noonan; Suzanne Bertera; Robert Lakomy; Henry Cohen; Derrick Wells; Massimo Trucco; Yong Fan

Collaboration


Dive into the Robert Lakomy's collaboration.

Top Co-Authors

Avatar

Massimo Trucco

Allegheny Health Network

View shared research outputs
Top Co-Authors

Avatar

Alexis Styche

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jo Harnaha

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Edwin Klein

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge